BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29473469)

  • 1. Immunotherapy for thoracic oncology gone viral.
    Patel MR
    Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
    Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
    Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viroimmunotherapy of Thoracic Cancers.
    Dash AS; Patel MR
    Biomedicines; 2017 Jan; 5(1):. PubMed ID: 28536345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiating prostate cancer immunotherapy with oncolytic viruses.
    Lee P; Gujar S
    Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.
    Morales-Molina Á; Gambera S; Cejalvo T; Moreno R; Rodríguez-Milla MÁ; Perisé-Barrios AJ; García-Castro J
    Cancer Immunol Immunother; 2018 Oct; 67(10):1589-1602. PubMed ID: 30066102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
    Gujar S; Bell J; Diallo JS
    Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talimogene laherparepvec: First in class oncolytic virotherapy.
    Conry RM; Westbrook B; McKee S; Norwood TG
    Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.
    Bhatt DK; Daemen T
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies.
    Garofalo M; Villa A; Rizzi N; Kuryk L; Mazzaferro V; Ciana P
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30322158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fighting Cancer with Mathematics and Viruses.
    Santiago DN; Heidbuechel JPW; Kandell WM; Walker R; Djeu J; Engeland CE; Abate-Daga D; Enderling H
    Viruses; 2017 Aug; 9(9):. PubMed ID: 28832539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.